Cedric Hermans/LinkedIn
Aug 13, 2025, 23:32
Cedric Hermans Shares His Vision for the Use of APCC During Emicizumab Prophylaxis
Cedric Hermans, Head of Haemophilia Centre at the Cliniques Universitaires Saint-Luc in Brussels, recently shared on LinkedIn:
”Personal commentary on the recent important paper by Robert Sidonio et al. on APCC in patients receiving emicizumab prophylaxis published in RPTH.”
Read the full article here.
Article: Cautious use of activated prothrombin complex concentrate in patients receiving emicizumab: new evidence and clinical considerations
Author: Cedric Hermans
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Feb 24, 2026, 13:59Riitta Lassila: How APAC Impacts the Interplay Between Complement and Coagulation
-
Feb 24, 2026, 13:29Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH
-
Feb 24, 2026, 13:28EAHAD Welcomes New Members to the Nurses Committee
-
Feb 24, 2026, 13:25AbQader Bedil: Donor Ferritin Testing and Iron Care
-
Feb 24, 2026, 12:53Tagreed Alkaltham։ Blood Is a Naturally Integrated and Adaptive Physiological System
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026